Precision reactivation of fetal hemoglobin: expanding the gene-editing landscape for β-thalassemia

References

[1] Frangoul H,Walters MC.CRISPR-Cas12a gene editing of HBG1 and HBG2 promoters to treat β-thalassemia.N Engl J Med2026;394:1292-301

[2] Hanna R,Pineiro L.CRISPR-Cas12a gene editing of HBG1 and HBG2 promoters to treat sickle cell disease.N Engl J Med2026;394:1281-91

[3] Sankaran VG,Xu J.Human fetal hemoglobin expression is regulated by the developmental stage-specific repressor BCL11A.Science2008;322:1839-42

[4] Locatelli F,Wall D.Exagamglogene autotemcel for transfusion-dependent β-thalassemia.N Engl J Med2024;390:1663-76

[5] Frangoul H,Cappellini MD.CRISPR-Cas9 gene editing for sickle cell disease and β-thalassemia.N Engl J Med2021;384:252-60

[6] Yu Y,Khaled W.Bcl11a is essential for lymphoid development and negatively regulates p53.J Exp Med2012;209:2467-83 PMCID:PMC3526365

[7] Jang Y,Palmer LE.BCL11A-deficient human erythropoiesis is impaired in vitro and after xenotransplantation into mice.Blood Adv2025;9:2722-32 PMCID:PMC12159907

[8] Janoudi T,Wu M.Nonclinical evaluation of HBG1/2 and BCL11A as genome-editing targets for the treatment of β-hemoglobinopathies.Blood Adv2025;9:808-13 PMCID:PMC11869951

[9] Martyn GE,Yang L.Natural regulatory mutations elevate the fetal globin gene via disruption of BCL11A or ZBTB7A binding.Nat Genet2018;50:498-503

[10] Thein SL.Discovering the genetics underlying foetal haemoglobin production in adults.Br J Haematol2009;145:455-67

[11] Traxler EA,Wang Y.A genome-editing strategy to treat β-hemoglobinopathies that recapitulates a mutation associated with a benign genetic condition.Nat Med2016;22:987-90 PMCID:PMC5706766

[12] Métais J,Mayuranathan T.Genome editing of HBG1 and HBG2 to induce fetal hemoglobin.Blood Adv2019;3:3379-92 PMCID:PMC6855127

[13] Jinek M,Fonfara I,Doudna JA.A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity.Science2012;337:816-21 PMCID:PMC6286148

[14] Haapaniemi E,Persson J,Taipale J.CRISPR-Cas9 genome editing induces a p53-mediated DNA damage response.Nat Med2018;24:927-30

[15] Kosicki M,Bradley A.Repair of double-strand breaks induced by CRISPR-Cas9 leads to large deletions and complex rearrangements.Nat Biotechnol2018;36:765-71

[16] Leibowitz ML,Doerfler PA.Chromothripsis as an on-target consequence of CRISPR-Cas9 genome editing.Nat Genet2021;53:895-905 PMCID:PMC8192433

[17] Zetsche B,Abudayyeh OO.Cpf1 is a single RNA-guided endonuclease of a class 2 CRISPR-cas system.Cell2015;163:759-71 PMCID:PMC4638220

[18] Kleinstiver BP,Walton RT.Engineered CRISPR-Cas12a variants with increased activities and improved targeting ranges for gene, epigenetic and base editing.Nat Biotechnol2019;37:276-82 PMCID:PMC6401248

[19] Kim HK,Song M.Deep learning improves prediction of CRISPR-Cpf1 guide RNA activity.Nat Biotechnol2018;36:239-41

[20] Komor AC,Packer MS,Liu DR.Programmable editing of a target base in genomic DNA without double-stranded DNA cleavage.Nature2016;533:420-4 PMCID:PMC4873371

[21] Gaudelli NM,Rees HA.Programmable base editing of A•T to G•C in genomic DNA without DNA cleavage.Nature2017;551:464-71 PMCID:PMC5726555

[22] Mayuranathan T,Feng R.Potent and uniform fetal hemoglobin induction via base editing.Nat Genet2023;55:1210-20 PMCID:PMC10722557

[23] Gupta AO,Frangoul H.Base editing of HBG1 and HBG2 promoters for sickle cell disease.N Engl J Med2026;394:1824-35

[24] Anzalone AV,Davis JR.Search-and-replace genome editing without double-strand breaks or donor DNA.Nature2019;576:149-57

[25] Qi LS,Gilbert LA.Repurposing CRISPR as an RNA-guided platform for sequence-specific control of gene expression.Cell2013;152:1173-83 PMCID:PMC3664290

[26] Hilton IB,Vockley CM.Epigenome editing by a CRISPR-Cas9-based acetyltransferase activates genes from promoters and enhancers.Nat Biotechnol2015;33:510-7 PMCID:PMC4430400

[27] Charlesworth CT,Dever DP.Identification of preexisting adaptive immunity to Cas9 proteins in humans.Nat Med2019;25:249-54 PMCID:PMC7199589

[28] Tsai SQ,Nguyen NT.GUIDE-seq enables genome-wide profiling of off-target cleavage by CRISPR-Cas nucleases.Nat Biotechnol2014;33:187-97 PMCID:PMC4320685

[29] Turchiano G,Klermund J.Quantitative evaluation of chromosomal rearrangements in gene-edited human stem cells by CAST-Seq.Cell Stem Cell2021;28:1136-47.e5

[30] Höijer I,Östlund R.CRISPR-Cas9 induces large structural variants at on-target and off-target sites in vivo that segregate across generations.Nat Commun2022;13:627 PMCID:PMC8810904

[31] Goyal S,Schmidt M.Acute myeloid leukemia case after gene therapy for sickle cell disease.N Engl J Med2022;386:138-47

[32] Czechowicz A,Scheck A.Selective hematopoietic stem cell ablation using CD117-antibody-drug-conjugates enables safe and effective transplantation with immunity preservation.Nat Commun2019;10:617 PMCID:PMC6365495

[33] Breda L,Triebwasser MP.In vivo hematopoietic stem cell modification by mRNA delivery.Science2023;381:436-43 PMCID:PMC10567133

[34] Musunuru K,Wang X.Patient-specific in vivo gene editing to treat a rare genetic disease.N Engl J Med2025;392:2235-43

[35] Gootenberg JS,Lee JW.Nucleic acid detection with CRISPR-Cas13a/C2c2.Science2017;356:438-42 PMCID:PMC5526198

[36] Salodkar D,Nair A.Single-step CRISPR/Cas13a assay for detection of small RNAs in saliva: a proof-of-concept study.Cancer Genetics2026;300-1:67-71

[37] Sonkin D,Teicher BA.Cancer treatments: past, present, and future.Cancer Genetics2024;286-7:18-24 PMCID:PMC11338712

[38] Thompson AA,Kwiatkowski J.Gene therapy in patients with transfusion-dependent β-thalassemia.N Engl J Med2018;378:1479-93

[39] Locatelli F,Kwiatkowski JL.Betibeglogene autotemcel gene therapy for non-β⁰/β⁰ genotype β-thalassemia.N Engl J Med2022;386:415-27

[40] Kwiatkowski JL,Schneiderman J.Long-term efficacy and safety results of betibeglogene autotemcel gene therapy for transfusion-dependent β-thalassemia.Blood2026;147:2203-14